# Tae-You Kim

Source: https://onco.cc/people/kim-tae-you/  
OnCo record `kim-tae-you` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A GI oncologist and genomics researcher who leads precision oncology and colorectal cancer trials at Seoul National University.

## Summary

Tae-You Kim is Professor of Internal Medicine at Seoul National University Hospital, working in gastrointestinal oncology and cancer genomics. His group studies the genomic and epigenetic landscape of colorectal and gastric cancer and runs biomarker-driven trials using comprehensive genomic profiling, contributing to the Korean precision oncology programme and to global colorectal studies. His publications include a single-centre phase 2 study of gemcitabine and cisplatin plus durvalumab, with or without tremelimumab, in chemotherapy-naive advanced biliary tract cancer. His interests are colorectal cancer, gastric cancer, cancer genomics and precision oncology.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Internal Medicine; gastrointestinal oncology and cancer genomics
- Specialisms: Colorectal cancer; Gastric cancer; Cancer genomics; Precision oncology

## Sources

- Seoul National University Hospital: https://www.snuh.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TY%5BAuthor%5D%20Seoul%20National%20University%20colorectal

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/)
- institutions: [Seoul National University Hospital](https://onco.cc/institutions/snuh/)
- key papers: [IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer](https://onco.cc/key-papers/paper-imbrave150-nejm-2020/)

---
JSON: https://onco.cc/api/v1/entities/kim-tae-you.json